Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biotronik's absorbable stent shows 1-year promise:

This article was originally published in Clinica

Executive Summary

One-year follow-up data from a clinical trial of Biotronik's absorbable metal stent (AMS) are continuing to support the device, the firm has reported. The European study, which is testing the stent as a treatment for blocked arteries below the knee, revealed that after 12 months there was a primary vessel patency rate of 72.4% and a limb salvage rate of 94.7%. The Berlin, Germany firm said it was now preparing to start a randomised trial called INSIGHT-AMS within the second quarter of this year. The study, which will assess the six-month patency results of patients with infra-popliteal occlusion, is expected to result in Biotronik CE-marking the AMS technology for sale in Europe.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts